Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
1.470
+0.020 (1.38%)
At close: Oct 9, 2026, 4:00 PM EDT
1.460
-0.010 (-0.68%)
After-hours: Oct 9, 2026, 7:17 PM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $54.08K in the twelve months ending June 30, 2026, down -25.00% year-over-year. In the year 2025, Silo Pharma had annual revenue of $72.10K. That makes Silo Pharma the 46,466th largest company in the world by revenue and 6,920th in the United States.
Revenue (ttm)
$54.08K
Revenue Growth
-25.00%
P/S Ratio
43.17
Revenue / Employee
$18,026
Employees
3
Market Cap
2.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.10K | - | - |
| Dec 31, 2024 | 72.10K | - | - |
| Dec 31, 2023 | 72.10K | - | - |
| Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
| Dec 31, 2021 | 71.26K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| PMGC Holdings | 2.58M |
| GeoVax Labs | 852.28K |
| SciSparc | 679.00K |
| Onconetix | 645.82K |
| BioRestorative Therapies | 357.87K |
| VivoSim Labs | 112.00K |
| Alaunos Therapeutics | 3.00K |
SILO News
- 9 days ago - Silo Pharma’s QwikAgents expands AI agent platform with Nvidia model support - TheFly
- 9 days ago - Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility - GlobeNewsWire
- 21 days ago - Silo Pharma receives U.S. patent allowance for SPC-15 PTSD treatment - TheFly
- 21 days ago - Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio - GlobeNewsWire
- 4 weeks ago - Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum - GlobeNewsWire
- 7 weeks ago - Silo Pharma receives notice of allowance from CIPO for PTSD treatment - TheFly
- 7 weeks ago - Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - GlobeNewsWire
- 2 months ago - Silo Pharma granted European patent covering PTSD therapy - TheFly